ziprasidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2865 146939-27-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ziprasidone
  • zaprasidone
  • ziprasidone hydrochloride
  • ziprasidone mesylate
  • geodon
  • ziprasidone HCl
  • ziprasidone mesilate
a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone
  • Molecular weight: 412.94
  • Formula: C21H21ClN4OS
  • CLOGP: 4.86
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 48.47
  • ALOGS: -4.76
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
80 mg O
40 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.21 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.36 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.10 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AKT2,AKT3,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MARK4,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TTK 38
kinase-selectivity-class AXL,GRK2,STK33 3
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1

Approvals:

DateAgencyCompanyOrphan
Feb. 5, 2001 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood prolactin abnormal 1501.63 20.87 297 19213 2969 90605968
Sexual dysfunction 1478.58 20.87 313 19197 4491 90604446
Dystonia 1447.17 20.87 391 19119 16428 90592509
Anosognosia 1225.20 20.87 254 19256 3268 90605669
Disturbance in social behaviour 1147.50 20.87 248 19262 3940 90604997
Sedation 1115.86 20.87 411 19099 47760 90561177
Dyskinesia 1050.70 20.87 366 19144 36168 90572769
Metabolic disorder 1029.99 20.87 253 19257 7217 90601720
Personality change 959.15 20.87 238 19272 7083 90601854
Suicide attempt 784.34 20.87 363 19147 75036 90533901
Tardive dyskinesia 781.92 20.87 220 19290 10710 90598227
Completed suicide 505.49 20.87 340 19170 144718 90464219
Blood glucose increased 468.96 20.87 278 19232 94968 90513969
Extrapyramidal disorder 432.43 20.87 154 19356 16149 90592788
Akathisia 427.95 20.87 139 19371 11020 90597917
Neuroleptic malignant syndrome 398.11 20.87 142 19368 14954 90593983
Orthostatic hypertension 360.07 20.87 68 19442 517 90608420
Metabolic syndrome 306.70 20.87 73 19437 1809 90607128
Parkinsonism 270.64 20.87 105 19405 13960 90594977
Electrocardiogram QT prolonged 245.12 20.87 167 19343 72289 90536648
Diabetes mellitus 225.32 20.87 152 19358 64723 90544214
Suicidal ideation 203.02 20.87 150 19360 73705 90535232
Insurance issue 169.80 20.87 70 19440 10888 90598049
Oculogyric crisis 159.59 20.87 46 19464 2433 90606504
Impulse-control disorder 149.20 20.87 36 19474 946 90607991
Psychotic disorder 147.79 20.87 89 19421 31141 90577796
Agitation 138.29 20.87 115 19395 66983 90541954
Tremor 135.73 20.87 166 19344 153007 90455930
Posture abnormal 133.96 20.87 41 19469 2670 90606267
Galactorrhoea 119.54 20.87 43 19467 4629 90604308
Mania 119.09 20.87 59 19451 14065 90594872
Blood prolactin increased 118.17 20.87 40 19470 3597 90605340
Hallucination, auditory 115.07 20.87 60 19450 15915 90593022
Respiratory arrest 108.35 20.87 75 19435 33236 90575701
Personality change due to a general medical condition 107.10 20.87 22 19488 268 90608669
Dyslipidaemia 105.84 20.87 49 19461 10058 90598879
Cardio-respiratory arrest 99.60 20.87 93 19417 63047 90545890
Substance abuse 99.16 20.87 39 19471 5367 90603570
Paranoia 91.59 20.87 48 19462 12860 90596077
Arthralgia 90.00 20.87 28 19482 778494 89830443
Coma 88.61 20.87 93 19417 72539 90536398
Torsade de pointes 81.61 20.87 47 19463 15135 90593802
Pain 79.96 20.87 59 19451 996282 89612655
Somnolence 79.51 20.87 153 19357 208931 90400006
Intentional overdose 78.71 20.87 99 19411 93735 90515202
Joint swelling 77.21 20.87 9 19501 503291 90105646
Hyperprolactinaemia 75.09 20.87 32 19478 5401 90603536
Depression 73.36 20.87 184 19326 300417 90308520
Anxiety 72.88 20.87 187 19323 309585 90299352
Adverse drug reaction 71.90 20.87 106 19404 116595 90492342
Cardiac arrest 68.55 20.87 98 19412 104837 90504100
Toxicity to various agents 66.90 20.87 173 19337 287673 90321264
Delusion 66.90 20.87 40 19470 13800 90595137
Overdose 64.39 20.87 119 19391 157590 90451347
Systemic lupus erythematosus 62.17 20.87 4 19506 361892 90247045
Drug ineffective 61.57 20.87 507 19003 1383791 89225146
Diarrhoea 60.55 20.87 68 19442 939122 89669815
Arthropathy 60.19 20.87 5 19505 366237 90242700
Weight increased 60.06 20.87 212 19298 417715 90191222
Pneumonia 59.03 20.87 32 19478 638027 89970910
Cognitive disorder 57.83 20.87 73 19437 69334 90539603
Abnormal behaviour 57.75 20.87 44 19466 22584 90586353
Peripheral swelling 57.24 20.87 10 19500 413096 90195841
Rheumatoid arthritis 56.80 20.87 6 19504 362608 90246329
Condition aggravated 56.10 20.87 265 19245 595280 90013657
Rapid eye movement sleep behaviour disorder 52.81 20.87 13 19497 372 90608565
Alopecia 51.65 20.87 21 19489 495050 90113887
General physical health deterioration 50.51 20.87 8 19502 355107 90253830
Product use issue 50.30 20.87 6 19504 329913 90279024
Catatonia 50.16 20.87 25 19485 6031 90602906
Abdominal discomfort 48.58 20.87 21 19489 477307 90131630
Nasopharyngitis 48.10 20.87 14 19496 407090 90201847
Treatment failure 47.66 20.87 5 19505 303923 90305014
Wound 47.48 20.87 5 19505 302975 90305962
Aggression 47.36 20.87 42 19468 26626 90582311
Swelling 46.68 20.87 16 19494 419042 90189895
Hallucination 46.63 20.87 64 19446 65895 90543042
Pericarditis 46.34 20.87 3 19507 270148 90338789
Off label use 45.51 20.87 107 19403 1102145 89506792
Blood triglycerides increased 44.77 20.87 31 19479 13730 90595207
Psychomotor hyperactivity 44.38 20.87 30 19480 12783 90596154
Mental disorder 44.15 20.87 44 19466 32274 90576663
Sinusitis 43.97 20.87 10 19500 343078 90265859
Muscle rigidity 43.68 20.87 31 19479 14278 90594659
Insomnia 43.50 20.87 164 19346 333310 90275627
Infarction 42.48 20.87 18 19492 2995 90605942
Cardiac hypertrophy 42.41 20.87 14 19496 1164 90607773
Glossodynia 42.00 20.87 9 19501 321770 90287167
Symptom recurrence 40.84 20.87 19 19491 3940 90604997
Infection 40.02 20.87 14 19496 362080 90246857
Maternal exposure during pregnancy 39.66 20.87 14 19496 360049 90248888
Mobility decreased 39.63 20.87 4 19506 250730 90358207
Seizure 38.82 20.87 95 19415 152534 90456403
Restlessness 38.74 20.87 43 19467 35677 90573260
Mental status changes 37.22 20.87 47 19463 44632 90564305
Distributive shock 37.09 20.87 17 19493 3407 90605530
Rhabdomyolysis 36.63 20.87 50 19460 51206 90557731
Blister 35.67 20.87 6 19504 254992 90353945
Stomatitis 35.20 20.87 8 19502 274690 90334247
Reduced facial expression 35.15 20.87 15 19495 2538 90606399
Obesity 35.01 20.87 73 19437 105434 90503503
Rabbit syndrome 34.38 20.87 9 19501 331 90608606
Hypersensitivity 33.73 20.87 29 19481 454648 90154289
Drug withdrawal syndrome 33.63 20.87 36 19474 28687 90580250
Product substitution issue 33.25 20.87 29 19481 17979 90590958
Swollen tongue 33.09 20.87 45 19465 45911 90563026
Urticaria 33.02 20.87 13 19497 312721 90296216
Intentional product use issue 32.91 20.87 4 19506 216888 90392049
Pyrexia 32.36 20.87 58 19452 660427 89948510
Abulia 31.98 20.87 10 19500 699 90608238
Drug intolerance 31.46 20.87 30 19480 447561 90161376
Pruritus 30.83 20.87 43 19467 541482 90067455
Irritability 30.48 20.87 38 19472 35624 90573313
Wheezing 30.37 20.87 7 19503 238073 90370864
Fatigue 30.21 20.87 137 19373 1153886 89455051
Tachyphrenia 30.21 20.87 12 19498 1694 90607243
Gastrointestinal disorder 29.98 20.87 9 19501 256678 90352259
Abdominal pain 29.63 20.87 25 19485 395696 90213241
Hepatic enzyme increased 29.28 20.87 21 19489 360715 90248222
Organ failure 29.26 20.87 14 19496 3091 90605846
Lethargy 28.75 20.87 50 19460 63089 90545848
Blood creatine phosphokinase increased 28.67 20.87 36 19474 33987 90574950
Torticollis 28.66 20.87 13 19497 2545 90606392
Shock 28.41 20.87 33 19477 28745 90580192
Exposure via ingestion 28.14 20.87 13 19497 2654 90606283
Cogwheel rigidity 27.79 20.87 12 19498 2090 90606847
Bruxism 27.51 20.87 15 19495 4348 90604589
Pain in extremity 27.45 20.87 34 19476 450495 90158442
Drooling 26.93 20.87 15 19495 4531 90604406
Thrombocytopenia 26.89 20.87 6 19504 208719 90400218
Internal fixation of fracture 26.52 20.87 9 19501 815 90608122
Discomfort 26.44 20.87 13 19497 274322 90334615
Fibromyalgia 26.43 20.87 6 19504 206263 90402674
Trismus 26.11 20.87 15 19495 4806 90604131
Withdrawal syndrome 25.96 20.87 28 19482 22496 90586441
Posturing 25.60 20.87 8 19502 558 90608379
Inflammation 25.43 20.87 4 19506 178588 90430349
Lacunar infarction 25.22 20.87 13 19497 3364 90605573
Echolalia 25.14 20.87 7 19503 326 90608611
Sinus bradycardia 24.86 20.87 24 19486 16928 90592009
Mood altered 24.64 20.87 24 19486 17120 90591817
Osteoarthritis 24.47 20.87 6 19504 195724 90413213
Cough 24.47 20.87 26 19484 368936 90240001
Suicidal behaviour 24.32 20.87 12 19498 2832 90606105
Bipolar disorder 24.09 20.87 18 19492 8967 90599970
Asthma 24.06 20.87 11 19499 242149 90366788
Amenorrhoea 23.93 20.87 20 19490 11702 90597235
Thinking abnormal 23.92 20.87 20 19490 11712 90597225
Drug screen positive 23.92 20.87 13 19497 3744 90605193
Liver injury 23.88 20.87 4 19506 170563 90438374
Diabetic coma 23.47 20.87 8 19502 734 90608203
Stereotypy 22.97 20.87 7 19503 449 90608488
Female sexual dysfunction 22.96 20.87 5 19505 82 90608855
Rash 22.94 20.87 91 19419 796009 89812928
Headache 22.78 20.87 102 19408 862644 89746293
Muscle twitching 22.64 20.87 27 19483 24175 90584762
Malaise 22.43 20.87 59 19451 585927 90023010
Coprolalia 22.14 20.87 4 19506 23 90608914
Granulocytopenia 22.11 20.87 15 19495 6426 90602511
Musculoskeletal pain 21.90 20.87 5 19505 171246 90437691
Muscle tightness 21.57 20.87 20 19490 13419 90595518
Gestational diabetes 21.49 20.87 18 19492 10564 90598373
Therapeutic product effect decreased 21.43 20.87 17 19493 277554 90331383
Hyperdynamic left ventricle 21.38 20.87 6 19504 288 90608649
Poisoning 21.30 20.87 21 19489 15196 90593741
Obsessive thoughts 20.99 20.87 7 19503 601 90608336

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Akathisia 499.89 23.51 172 14314 10279 42596570
Dystonia 451.23 23.51 168 14318 12622 42594227
Antipsychotic drug level below therapeutic 441.14 23.51 119 14367 3085 42603764
Disinhibition 418.14 23.51 119 14367 3776 42603073
Therapeutic product effect variable 416.46 23.51 113 14373 2996 42603853
Euphoric mood 411.64 23.51 132 14354 6321 42600528
Obsessive-compulsive disorder 397.82 23.51 130 14356 6613 42600236
Suicide attempt 357.26 23.51 212 14274 45888 42560961
Increased appetite 336.20 23.51 123 14363 8783 42598066
Neuroleptic malignant syndrome 305.41 23.51 148 14338 21324 42585525
Dyskinesia 302.05 23.51 155 14331 25235 42581614
Anosognosia 284.64 23.51 67 14419 977 42605872
Blood prolactin abnormal 278.72 23.51 66 14420 989 42605860
Weight increased 275.71 23.51 254 14232 107729 42499120
Tardive dyskinesia 262.68 23.51 96 14390 6828 42600021
Disturbance in social behaviour 248.29 23.51 67 14419 1736 42605113
Extrapyramidal disorder 238.99 23.51 115 14371 16297 42590552
Sedation 214.82 23.51 132 14354 30343 42576506
Obesity 211.77 23.51 106 14380 16353 42590496
Sexual dysfunction 199.27 23.51 78 14408 6697 42600152
Metabolic disorder 183.86 23.51 67 14419 4721 42602128
Leukaemia 178.78 23.51 69 14417 5703 42601146
Schizoaffective disorder 153.55 23.51 47 14439 1923 42604926
Dyslipidaemia 149.31 23.51 70 14416 9348 42597501
Aggression 142.76 23.51 119 14367 44044 42562805
Personality change 141.01 23.51 58 14428 5661 42601188
Irritability 137.59 23.51 97 14389 28031 42578818
Completed suicide 133.40 23.51 164 14322 96301 42510548
Psychotic disorder 132.02 23.51 96 14390 29112 42577737
Suicidal ideation 131.81 23.51 118 14368 48043 42558806
Priapism 121.65 23.51 54 14432 6353 42600496
Electrocardiogram QT prolonged 110.95 23.51 107 14379 47838 42559011
Catatonia 107.07 23.51 49 14437 6190 42600659
Oppositional defiant disorder 106.43 23.51 27 14459 545 42606304
Leukopenia 106.39 23.51 129 14357 74617 42532232
Therapeutic product effect incomplete 105.17 23.51 125 14361 70814 42536035
Prescribed overdose 103.98 23.51 61 14425 12866 42593983
Decreased eye contact 103.82 23.51 26 14460 497 42606352
Homicidal ideation 103.19 23.51 38 14448 2756 42604093
Hallucination, auditory 101.14 23.51 63 14423 14801 42592048
Bruxism 100.89 23.51 35 14451 2134 42604715
Agitation 99.77 23.51 116 14370 64198 42542651
Blood prolactin increased 95.12 23.51 34 14452 2264 42604585
Delusion 94.11 23.51 60 14426 14674 42592175
Toxicity to various agents 90.21 23.51 223 14263 228913 42377936
Drug ineffective 81.28 23.51 424 14062 629773 41977076
Oculogyric crisis 80.24 23.51 28 14458 1737 42605112
Trismus 77.09 23.51 31 14455 2853 42603996
Serotonin syndrome 76 23.51 66 14420 25779 42581070
Paranoia 74.72 23.51 51 14435 13975 42592874
Crying 64.48 23.51 35 14451 6359 42600490
Diarrhoea 63.89 23.51 39 14447 460810 42146039
Mania 62.55 23.51 41 14445 10506 42596343
Choreoathetosis 59.82 23.51 20 14466 1089 42605760
Psychomotor hyperactivity 58.73 23.51 40 14446 10918 42595931
Anaemia 58.64 23.51 12 14474 280266 42326583
Blood glucose increased 58.20 23.51 96 14390 73603 42533246
Pneumonia 58.10 23.51 36 14450 422113 42184736
Parkinsonism 57.46 23.51 39 14447 10584 42596265
Spasmodic dysphonia 56.25 23.51 16 14470 505 42606344
Coordination abnormal 54.45 23.51 34 14452 8016 42598833
Anxiety 51.47 23.51 120 14366 118440 42488409
Speech disorder 51.02 23.51 56 14430 29065 42577784
Swollen tongue 48.34 23.51 47 14439 21184 42585665
Dacryostenosis congenital 47.12 23.51 9 14477 43 42606806
Tic 44.95 23.51 20 14466 2363 42604486
Abnormal behaviour 44.84 23.51 50 14436 26401 42580448
Off label use 42.38 23.51 97 14389 638238 41968611
Mood altered 41.21 23.51 32 14454 10686 42596163
Blood creatine phosphokinase increased 40.91 23.51 65 14421 48273 42558576
Type 2 diabetes mellitus 40.39 23.51 40 14446 18431 42588418
Muscle rigidity 39.96 23.51 33 14453 12026 42594823
Pruritus 39.61 23.51 8 14478 188763 42418086
Schizophrenia 39.48 23.51 31 14455 10519 42596330
Affect lability 37.64 23.51 21 14465 4023 42602826
Tremor 37.63 23.51 94 14392 96835 42510014
Overdose 36.66 23.51 98 14388 105166 42501683
Granulocytopenia 35.84 23.51 25 14461 7089 42599760
Anger 35.77 23.51 32 14454 12986 42593863
Acute kidney injury 35.19 23.51 44 14442 367293 42239556
Torticollis 34.12 23.51 14 14472 1356 42605493
Blood triglycerides increased 33.97 23.51 34 14452 15862 42590987
Arthralgia 33.38 23.51 14 14472 205224 42401625
Hallucination, tactile 33.29 23.51 11 14475 577 42606272
Hypotonia neonatal 33.04 23.51 14 14472 1470 42605379
Febrile neutropenia 32.99 23.51 11 14475 185692 42421157
Social anxiety disorder 32.97 23.51 11 14475 595 42606254
Pyrexia 32.97 23.51 52 14434 393990 42212859
Disease progression 32.50 23.51 5 14481 143651 42463198
Death 31.67 23.51 71 14415 471114 42135735
Hyperkinesia 31.41 23.51 15 14471 2083 42604766
Thrombocytopenia 30.91 23.51 13 14473 190266 42416583
Cough 30.86 23.51 11 14475 178092 42428757
Grandiosity 30.85 23.51 9 14477 311 42606538
Gynaecomastia 30.84 23.51 29 14457 12538 42594311
Somnolence 30.25 23.51 111 14375 140994 42465855
Antipsychotic drug level increased 29.78 23.51 19 14467 4647 42602202
Rhabdomyolysis 29.58 23.51 75 14411 77944 42528905
Overweight 29.43 23.51 15 14471 2397 42604452
Feminisation acquired 29.34 23.51 6 14480 43 42606806
Persecutory delusion 29.13 23.51 17 14469 3547 42603302
Blunted affect 28.94 23.51 9 14477 388 42606461
Insomnia 28.77 23.51 97 14389 118156 42488693
Diabetes mellitus 28.46 23.51 63 14423 60024 42546825
Drug interaction 28.32 23.51 171 14315 266828 42340021
Malignant catatonia 27.66 23.51 9 14477 450 42606399
Bipolar disorder 25.10 23.51 16 14470 3906 42602943
Streptococcal infection 25.09 23.51 19 14467 6113 42600736
Depressed mood 24.86 23.51 35 14451 23349 42583500
Opisthotonus 24.81 23.51 9 14477 625 42606224
Asthenia 24.46 23.51 36 14450 280757 42326092
Nervousness 23.65 23.51 26 14460 13506 42593343
Poor quality sleep 23.58 23.51 22 14464 9418 42597431
Hyperhidrosis 23.57 23.51 76 14410 90436 42516413
Neonatal respiratory depression 23.54 23.51 8 14478 458 42606391

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood prolactin abnormal 1599.53 20.14 327 25960 3508 110559504
Dystonia 1475.61 20.14 446 25841 25359 110537653
Sexual dysfunction 1462.39 20.14 351 25936 8179 110554833
Anosognosia 1343.32 20.14 286 26001 3788 110559224
Disturbance in social behaviour 1243.39 20.14 279 26008 4779 110558233
Dyskinesia 1116.37 20.14 430 25857 51016 110511996
Sedation 1089.38 20.14 460 25827 69223 110493789
Metabolic disorder 1064.30 20.14 284 26003 10226 110552786
Personality change 990.64 20.14 271 26016 10731 110552281
Suicide attempt 851.47 20.14 438 25849 102956 110460056
Completed suicide 674.68 20.14 515 25772 241866 110321146
Neuroleptic malignant syndrome 603.02 20.14 246 26041 33813 110529199
Tardive dyskinesia 555.70 20.14 182 26105 13397 110549615
Akathisia 552.79 20.14 192 26095 16921 110546091
Extrapyramidal disorder 461.86 20.14 194 26093 28673 110534339
Blood glucose increased 457.34 20.14 321 25966 132175 110430837
Orthostatic hypertension 314.62 20.14 68 26219 967 110562045
Parkinsonism 305.09 20.14 134 26153 22053 110540959
Suicidal ideation 285.91 20.14 211 26076 93726 110469286
Metabolic syndrome 278.30 20.14 77 26210 3170 110559842
Electrocardiogram QT prolonged 277.29 20.14 220 26067 108740 110454272
Dyslipidaemia 227.85 20.14 99 26188 15866 110547146
Psychotic disorder 227.46 20.14 145 26142 50792 110512220
Oculogyric crisis 209.13 20.14 64 26223 3768 110559244
Aggression 193.70 20.14 139 26148 59071 110503941
Hallucination, auditory 183.31 20.14 100 26187 26297 110536715
Insurance issue 182.04 20.14 75 26212 10537 110552475
Antipsychotic drug level below therapeutic 176.04 20.14 47 26240 1688 110561324
Diabetes mellitus 175.83 20.14 163 26124 99218 110463794
Agitation 161.69 20.14 165 26122 112886 110450126
Blood prolactin increased 157.25 20.14 54 26233 4588 110558424
Irritability 151.25 20.14 110 26177 47699 110515313
Catatonia 144.87 20.14 65 26222 11235 110551777
Disinhibition 144.45 20.14 46 26241 3088 110559924
Obesity 138.22 20.14 152 26135 113199 110449813
Therapeutic product effect variable 138.20 20.14 43 26244 2675 110560337
Respiratory arrest 138.18 20.14 113 26174 58186 110504826
Delusion 137.83 20.14 80 26207 23675 110539337
Schizoaffective disorder 136.21 20.14 44 26243 3092 110559920
Euphoric mood 130.07 20.14 56 26231 8771 110554241
Drug ineffective 129.07 20.14 704 25583 1519836 109043176
Decreased eye contact 127.96 20.14 32 26255 883 110562129
Posture abnormal 124.99 20.14 45 26242 4393 110558619
Oppositional defiant disorder 124.09 20.14 28 26259 490 110562522
Obsessive-compulsive disorder 120.22 20.14 50 26237 7191 110555821
Weight increased 117.79 20.14 288 25999 419356 110143656
Impulse-control disorder 116.99 20.14 36 26251 2158 110560854
Paranoia 115.81 20.14 70 26217 22304 110540708
Toxicity to various agents 113.46 20.14 309 25978 480246 110082766
Adverse drug reaction 107.51 20.14 129 26158 105430 110457582
Increased appetite 104.69 20.14 57 26230 14920 110548092
Galactorrhoea 101.72 20.14 38 26249 4117 110558895
Homicidal ideation 99.23 20.14 36 26251 3591 110559421
Bruxism 98.41 20.14 39 26248 4955 110558057
Diarrhoea 96.47 20.14 78 26209 1139427 109423585
Mania 94.78 20.14 60 26227 20736 110542276
Psychomotor hyperactivity 93.66 20.14 59 26228 20218 110542794
Cardiac arrest 92.60 20.14 167 26120 196586 110366426
Personality change due to a general medical condition 91.84 20.14 20 26267 295 110562717
Cardio-respiratory arrest 90.31 20.14 124 26163 115712 110447300
Arthralgia 89.13 20.14 37 26250 779595 109783417
Anxiety 87.52 20.14 228 26059 344850 110218162
Overdose 87.42 20.14 180 26107 233614 110329398
Pneumonia 86.08 20.14 51 26236 876663 109686349
Tremor 80.71 20.14 160 26127 202072 110360940
Joint swelling 79.47 20.14 7 26280 442838 110120174
Pain 78.73 20.14 67 26220 954888 109608124
Trismus 75.29 20.14 35 26252 6561 110556451
Serotonin syndrome 74.98 20.14 81 26206 59072 110503940
Rhabdomyolysis 73.71 20.14 115 26172 120286 110442726
Priapism 72.86 20.14 33 26254 5828 110557184
Condition aggravated 72.79 20.14 356 25931 734480 109828532
Depression 70.75 20.14 200 26087 317135 110245877
Substance abuse 67.10 20.14 40 26247 12423 110550589
Granulocytopenia 66.36 20.14 40 26247 12675 110550337
Spasmodic dysphonia 65.14 20.14 17 26270 558 110562454
Mood altered 64.91 20.14 48 26239 21327 110541685
Muscle rigidity 64.22 20.14 50 26237 23981 110539031
Abnormal behaviour 63.20 20.14 61 26226 38978 110524034
Hyperprolactinaemia 63.19 20.14 31 26256 6544 110556468
Blood creatine phosphokinase increased 62.71 20.14 82 26205 72995 110490017
Cognitive disorder 59.81 20.14 88 26199 87423 110475589
Nasopharyngitis 59.30 20.14 11 26276 394350 110168662
Peripheral swelling 59.22 20.14 12 26275 404022 110158990
General physical health deterioration 57.61 20.14 15 26272 425280 110137732
Abdominal discomfort 57.10 20.14 12 26275 393846 110169166
Mental disorder 56.10 20.14 57 26230 38734 110524278
Torsade de pointes 56.05 20.14 45 26242 22555 110540457
Rheumatoid arthritis 55.79 20.14 4 26283 299609 110263403
Coma 55.35 20.14 100 26187 117769 110445243
Pyrexia 55.32 20.14 80 26207 898185 109664827
Choreoathetosis 54.59 20.14 19 26268 1679 110561333
Intentional overdose 54.24 20.14 106 26181 132395 110430617
Off label use 54.14 20.14 180 26107 1500005 109063007
Blood triglycerides increased 53.80 20.14 45 26242 23881 110539131
Insomnia 52.89 20.14 197 26090 360393 110202619
Anaemia 51.97 20.14 33 26254 547053 110015959
Alopecia 51.08 20.14 12 26275 364741 110198271
Arthropathy 50.35 20.14 5 26282 287517 110275495
Pruritus 47.59 20.14 41 26246 581519 109981493
Abdominal pain 47.28 20.14 32 26255 512957 110050055
Exposure via ingestion 46.78 20.14 23 26264 4877 110558135
Speech disorder 46.60 20.14 65 26222 61504 110501508
Somnolence 46.56 20.14 166 26121 297283 110265729
Stomatitis 46.54 20.14 5 26282 270237 110292775
Systemic lupus erythematosus 45.65 20.14 4 26283 254334 110308678
Crying 45.21 20.14 42 26245 25586 110537426
Hallucination 45.03 20.14 84 26203 101348 110461664
Rapid eye movement sleep behaviour disorder 45.00 20.14 13 26274 626 110562386
Persecutory delusion 44.12 20.14 24 26263 6267 110556745
Cough 43.62 20.14 28 26259 461613 110101399
Swelling 42.79 20.14 15 26272 351026 110211986
Torticollis 42.79 20.14 19 26268 3202 110559810
Leukaemia 42.76 20.14 25 26262 7493 110555519
Nausea 42.65 20.14 151 26136 1235539 109327473
Restlessness 41.99 20.14 59 26228 56200 110506812
Coordination abnormal 41.93 20.14 40 26247 25188 110537824
Grandiosity 41.76 20.14 12 26275 567 110562445
Febrile neutropenia 41.33 20.14 12 26275 316755 110246257
Sinusitis 41.06 20.14 10 26277 296678 110266334
Drug interaction 40.90 20.14 230 26057 499953 110063059
Infection 40.01 20.14 18 26269 362182 110200830
Hyperkinesia 39.80 20.14 18 26269 3166 110559846
Malignant catatonia 39.41 20.14 12 26275 694 110562318
Malaise 39.22 20.14 62 26225 671757 109891255
Thrombocytopenia 39.07 20.14 17 26270 348868 110214144
Pain in extremity 39.04 20.14 35 26252 487083 110075929
Wound 38.72 20.14 5 26282 234432 110328580
Tic 38.21 20.14 18 26269 3475 110559537
Swollen tongue 37.40 20.14 58 26229 60304 110502708
Intentional product use issue 37.07 20.14 7 26280 247899 110315113
Mobility decreased 37.04 20.14 6 26281 237416 110325596
Rabbit syndrome 36.93 20.14 10 26277 379 110562633
Maternal exposure during pregnancy 36.44 20.14 8 26279 254875 110308137
Symptom recurrence 35.69 20.14 19 26268 4753 110558259
Anger 35.18 20.14 32 26255 18975 110544037
Urticaria 34.97 20.14 16 26271 318841 110244171
Blister 34.90 20.14 6 26281 227370 110335642
Fatigue 34.73 20.14 160 26127 1215798 109347214
Wheezing 34.55 20.14 9 26278 255221 110307791
Reduced facial expression 34.45 20.14 17 26270 3634 110559378
Gastrointestinal disorder 33.78 20.14 8 26279 241944 110321068
Lethargy 33.70 20.14 71 26216 93505 110469507
Rash 33.42 20.14 93 26194 820871 109742141
Schizophrenia 33.26 20.14 33 26254 21793 110541219
Pericarditis 33.16 20.14 6 26281 219108 110343904
Contraindicated product administered 33.14 20.14 9 26278 248258 110314754
Headache 33.00 20.14 104 26183 882273 109680739
Disease progression 32.28 20.14 9 26278 244025 110318987
Abdominal pain upper 31.85 20.14 22 26265 349089 110213923
Social anxiety disorder 31.79 20.14 11 26276 955 110562057
Asthma 31.71 20.14 10 26277 250281 110312731
Mental status changes 31.26 20.14 61 26226 76061 110486951
Hallucination, tactile 31.26 20.14 11 26276 1004 110562008
Infarction 31.23 20.14 18 26269 5251 110557761
Renal impairment 31.16 20.14 4 26283 188441 110374571
Asthenia 31.14 20.14 74 26213 688925 109874087
Cardiac hypertrophy 30.83 20.14 13 26274 1934 110561078
Treatment noncompliance 30.60 20.14 59 26228 72931 110490081
Gynaecomastia 30.37 20.14 22 26265 9468 110553544
Treatment failure 30.26 20.14 14 26273 277220 110285792
Posturing 30.09 20.14 11 26276 1121 110561891
Inflammation 29.88 20.14 5 26282 193233 110369779
Hallucinations, mixed 29.77 20.14 21 26266 8672 110554340
Glossodynia 29.72 20.14 8 26279 221996 110341016
Dyspnoea 29.63 20.14 149 26138 1106723 109456289
Internal fixation of fracture 29.50 20.14 9 26278 524 110562488
Lung disorder 29.35 20.14 4 26283 180043 110382969
Thinking abnormal 29.02 20.14 26 26261 15114 110547898
Antipsychotic drug level increased 28.90 20.14 19 26268 6996 110556016
Abulia 28.50 20.14 11 26276 1302 110561710
Tachyphrenia 28.44 20.14 13 26274 2343 110560669
Drug intolerance 28.25 20.14 33 26254 406479 110156533
Affect lability 28.07 20.14 28 26259 18609 110544403
Musculoskeletal pain 27.72 20.14 5 26282 183018 110379994
Vomiting 27.67 20.14 117 26170 910558 109652454
Stereotypy 27.47 20.14 10 26277 1007 110562005
Fibromyalgia 27.38 20.14 4 26283 170905 110392107
COVID-19 27.33 20.14 12 26275 245048 110317964
Septic shock 26.89 20.14 3 26284 157525 110405487
Distributive shock 26.81 20.14 17 26270 5887 110557125
Feminisation acquired 26.72 20.14 5 26282 32 110562980
Osteoarthritis 25.56 20.14 6 26281 182617 110380395
Drug screen positive 25.53 20.14 17 26270 6393 110556619
Overweight 25.40 20.14 17 26270 6447 110556565
Depressed mood 25.30 20.14 49 26238 60760 110502252
Female sexual dysfunction 25.22 20.14 5 26282 45 110562967
Decreased appetite 24.92 20.14 47 26240 475799 110087213
Ventricular arrhythmia 24.83 20.14 20 26267 10067 110552945
Disturbance in attention 24.63 20.14 49 26238 61946 110501066
Alcohol abuse 24.42 20.14 15 26272 4914 110558098
Salivary hypersecretion 24.10 20.14 25 26262 17396 110545616
Gastrointestinal haemorrhage 24.05 20.14 5 26282 165513 110397499
Drooling 23.88 20.14 17 26270 7122 110555890
Contusion 23.64 20.14 13 26274 233348 110329664
Sinus bradycardia 23.62 20.14 32 26255 29451 110533561
Haemoglobin decreased 23.59 20.14 15 26272 248712 110314300
Streptococcal infection 23.49 20.14 20 26267 10870 110552142
Erythema 23.26 20.14 21 26266 291426 110271586
Discomfort 23.19 20.14 11 26276 214696 110348316
Product substitution issue 23.15 20.14 28 26259 23033 110539979
Myocarditis 23.14 20.14 32 26255 30023 110532989
Bradypnoea 23.12 20.14 18 26269 8631 110554381
Poverty of thought content 22.70 20.14 5 26282 78 110562934
Bipolar disorder 22.47 20.14 18 26269 8989 110554023
Hepatic enzyme increased 22.34 20.14 26 26261 320866 110242146
Sepsis 22.28 20.14 27 26260 327319 110235693
Type 2 diabetes mellitus 22.03 20.14 92 26195 177140 110385872
Night sweats 21.78 20.14 3 26284 133980 110429032
Obsessive thoughts 21.61 20.14 9 26278 1298 110561714
Myopathy toxic 21.49 20.14 9 26278 1316 110561696
Therapeutic product effect decreased 21.48 20.14 16 26271 244300 110318712
Pressure of speech 21.44 20.14 9 26278 1323 110561689
Sperm concentration decreased 21.29 20.14 5 26282 105 110562907
Diabetic coma 21.21 20.14 9 26278 1359 110561653
Injection site pain 20.99 20.14 8 26279 177914 110385098
Echolalia 20.98 20.14 7 26280 544 110562468
Corneal reflex decreased 20.96 20.14 7 26280 546 110562466
Poisoning 20.94 20.14 30 26257 29075 110533937
Muscle contractions involuntary 20.69 20.14 13 26274 4431 110558581
Arthritis 20.68 20.14 7 26280 167579 110395433
Interstitial lung disease 20.68 20.14 4 26283 139330 110423682
Intentional self-injury 20.49 20.14 34 26253 37395 110525617
Hyperdynamic left ventricle 20.49 20.14 7 26280 585 110562427

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dacryostenosis congenital 41.32 38.67 8 116 8 113821

Pharmacologic Action:

SourceCodeDescription
ATC N05AE04 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Indole derivatives
FDA EPC N0000175430 Atypical Antipsychotic
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D011619 Psychotropic Drugs
MeSH PA D012702 Serotonin Antagonists
MeSH PA D014149 Tranquilizing Agents
MeSH PA D014150 Antipsychotic Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018490 Serotonin Agents
MeSH PA D018492 Dopamine Antagonists
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35471 psychotropic drug
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:37956 histamine antagonist
CHEBI has role CHEBI:48279 serotonergic antagonist
CHEBI has role CHEBI:48561 dopaminergic antagonist
CHEBI has role CHEBI:48876 muscarinic antagonist
CHEBI has role CHEBI:38070 anti-arrhythmia drug

Related Drugs by ATC class:

N05AE Indole derivatives 4 drugs
lurasidonemolindoneoxypertinesertindole

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Mixed bipolar I disorder indication 16506000 DOID:3312
Schizophrenia indication 58214004 DOID:5419
Bipolar disorder in remission indication 85248005
Bipolar affective disorder, current episode manic indication 191618007
Agitation associated with Schizophrenia indication
Bipolar affective disorder, current episode depression off-label use 191627008 DOID:3312
Depression Treatment Adjunct off-label use
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Agranulocytosis contraindication 17182001 DOID:12987
Myocardial infarction contraindication 22298006 DOID:5844
Hypovolemia contraindication 28560003
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Dehydration contraindication 34095006
Dysphagia contraindication 40739000
Hypokalemia contraindication 43339004
Conduction disorder of the heart contraindication 44808001
Bradycardia contraindication 48867003
Hyperlipidemia contraindication 55822004 DOID:1168
Hepatic failure contraindication 59927004
Cerebrovascular disease contraindication 62914000 DOID:6713
Diabetes mellitus contraindication 73211009 DOID:9351
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Heart failure contraindication 84114007 DOID:6000
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Hypomagnesemia contraindication 190855004
Decompensated cardiac failure contraindication 195111005
Metabolic syndrome X contraindication 237602007 DOID:14221
Neutropenic disorder contraindication 303011007 DOID:1227
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Acquired torsion dystonia contraindication 433493000
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.26 acidic
pKa2 7.35 Basic
pKa3 0.27 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.32 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 9.40 WOMBAT-PK CHEMBL
Alpha-2C adrenergic receptor GPCR Ki 7.11 PDSP
Sodium-dependent dopamine transporter Transporter WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR Ki 5.80 PDSP
D(4) dopamine receptor GPCR ANTAGONIST Ki 7.30 WOMBAT-PK
5-hydroxytryptamine receptor 3A Ion channel Ki 6.40 WOMBAT-PK
Beta-1 adrenergic receptor GPCR Ki 5.59 PDSP
Beta-2 adrenergic receptor GPCR Ki 5.30 PDSP
D(1A) dopamine receptor GPCR Ki 8.02 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.30 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.92 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter IC50 7 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Ki 7.36 PDSP
5-hydroxytryptamine receptor 1A GPCR EC50 8.47 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR Ki 7.57 PDSP
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 8.89 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 7.22 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 8.30 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 8 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 7.32 PDSP
D(3) dopamine receptor GPCR ANTAGONIST Ki 8.14 WOMBAT-PK
D(1B) dopamine receptor GPCR Ki 6.82 PDSP
Histamine H1 receptor GPCR Ki 7.33 WOMBAT-PK
Histamine H2 receptor GPCR Ki 5.46 PDSP
Muscarinic acetylcholine receptor M1 GPCR Ki 6.55 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR Ki 5.52 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 5 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 5.80 PDSP
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 8.30 IUPHAR
5-hydroxytryptamine receptor 1D GPCR Ki 8.70 WOMBAT-PK
5-hydroxytryptamine receptor 1E GPCR Ki 6.44 WOMBAT-PK
Aspartate aminotransferase, cytoplasmic Enzyme IC50 5.27 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 8.05 PDSP
Histone H1.0 Nuclear other Ki 7.82 CHEMBL
5-hydroxytryptamine receptor 5A GPCR Ki 6.54 PDSP
Alpha-1A adrenergic receptor GPCR Ki 9.30 CHEMBL
Histamine H1 receptor GPCR Ki 7.80 CHEMBL
D(2) dopamine receptor GPCR Ki 8.32 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 9.38 CHEMBL
Histamine H1 receptor GPCR IC50 6.82 CHEMBL
Transporter Transporter Ki 7.32 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 7.96 CHEMBL

External reference:

IDSource
4021249 VUID
N0000148690 NUI
D02100 KEGG_DRUG
138982-67-9 SECONDARY_CAS_RN
199191-69-0 SECONDARY_CAS_RN
4021249 VANDF
4030214 VANDF
4030215 VANDF
C0380393 UMLSCUI
CHEBI:10119 CHEBI
XEF PDB_CHEM_ID
CHEMBL708 ChEMBL_ID
CHEMBL1375743 ChEMBL_ID
CHEMBL3989833 ChEMBL_ID
DB00246 DRUGBANK_ID
C092292 MESH_SUPPLEMENTAL_RECORD_UI
60854 PUBCHEM_CID
59 IUPHAR_LIGAND_ID
7155 INN_ID
6UKA5VEJ6X UNII
115698 RXNORM
16791 MMSL
187736 MMSL
331404 MMSL
41113 MMSL
d04747 MMSL
009104 NDDF
009105 NDDF
009579 NDDF
129479007 SNOMEDCT_US
373389002 SNOMEDCT_US
409356003 SNOMEDCT_US
409357007 SNOMEDCT_US
6UKA5VEJ6X INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0052 CAPSULE 20 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0054 CAPSULE 40 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0056 CAPSULE 60 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0058 CAPSULE 80 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0352 CAPSULE 20 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0354 CAPSULE 40 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0356 CAPSULE 60 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0358 CAPSULE 80 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3920 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAMUSCULAR NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3960 CAPSULE 20 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3980 CAPSULE 60 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3990 CAPSULE 80 mg ORAL NDA 32 sections
Ziprasidone HUMAN PRESCRIPTION DRUG LABEL 1 0904-6269 CAPSULE 20 mg ORAL ANDA 31 sections
Ziprasidone HUMAN PRESCRIPTION DRUG LABEL 1 0904-6270 CAPSULE 40 mg ORAL ANDA 31 sections
Ziprasidone HUMAN PRESCRIPTION DRUG LABEL 1 0904-6271 CAPSULE 60 mg ORAL ANDA 31 sections
Ziprasidone HUMAN PRESCRIPTION DRUG LABEL 1 0904-6272 CAPSULE 80 mg ORAL ANDA 31 sections
GEODON HUMAN PRESCRIPTION DRUG LABEL 1 16590-895 CAPSULE 20 mg ORAL NDA 34 sections
ziprasidone HUMAN PRESCRIPTION DRUG LABEL 1 16714-835 CAPSULE 20 mg ORAL ANDA 31 sections
ziprasidone HUMAN PRESCRIPTION DRUG LABEL 1 16714-836 CAPSULE 40 mg ORAL ANDA 31 sections
ziprasidone HUMAN PRESCRIPTION DRUG LABEL 1 16714-837 CAPSULE 60 mg ORAL ANDA 31 sections
ziprasidone HUMAN PRESCRIPTION DRUG LABEL 1 16714-838 CAPSULE 80 mg ORAL ANDA 31 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 21695-060 CAPSULE 20 mg ORAL NDA 34 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 21695-061 CAPSULE 40 mg ORAL NDA 34 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 21695-062 CAPSULE 60 mg ORAL NDA 34 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 21695-063 CAPSULE 80 mg ORAL NDA 34 sections
Ziprasidone Hydrochloride Human Prescription Drug Label 1 33342-144 CAPSULE 20 mg ORAL ANDA 31 sections
Ziprasidone Hydrochloride Human Prescription Drug Label 1 33342-145 CAPSULE 40 mg ORAL ANDA 31 sections
Ziprasidone Hydrochloride Human Prescription Drug Label 1 33342-146 CAPSULE 60 mg ORAL ANDA 31 sections
Ziprasidone Hydrochloride Human Prescription Drug Label 1 33342-147 CAPSULE 80 mg ORAL ANDA 31 sections
Ziprasidone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42254-169 CAPSULE 20 mg ORAL ANDA 29 sections